Vanguard Group Inc. grew its holdings in MiMedx Group, Inc (NASDAQ:MDXG – Free Report) by 5.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,184,262 shares of the company’s stock after buying an additional 382,623 shares during the period. Vanguard Group Inc.’s holdings in MiMedx Group were worth $48,637,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. State of Alaska Department of Revenue acquired a new stake in shares of MiMedx Group in the third quarter valued at approximately $54,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of MiMedx Group in the third quarter valued at approximately $84,000. Allianz Asset Management GmbH acquired a new stake in shares of MiMedx Group in the third quarter valued at approximately $82,000. Headlands Technologies LLC acquired a new stake in shares of MiMedx Group in the second quarter valued at approximately $72,000. Finally, Cresset Asset Management LLC acquired a new stake in shares of MiMedx Group in the third quarter valued at approximately $86,000. 79.15% of the stock is owned by institutional investors and hedge funds.
MiMedx Group Price Performance
Shares of NASDAQ MDXG opened at $3.56 on Friday. The firm has a market cap of $530.26 million, a P/E ratio of 17.80 and a beta of 1.46. The company has a current ratio of 5.39, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07. MiMedx Group, Inc has a 1-year low of $3.03 and a 1-year high of $7.99. The business’s 50 day moving average is $3.86 and its 200-day moving average is $5.43.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on MDXG. Cantor Fitzgerald cut their price objective on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. UBS Group set a $10.00 target price on MiMedx Group in a research note on Monday, February 23rd. Citigroup began coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating on the stock. Citizens Jmp lowered their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Finally, Lake Street Capital lowered their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.
Check Out Our Latest Analysis on MDXG
About MiMedx Group
MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.
MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.
Featured Stories
- Five stocks we like better than MiMedx Group
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc (NASDAQ:MDXG – Free Report).
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
